Galvus keeps chugging along, racking up respectable sales in spite of its never being approved in the US. I wonder if, behind closed doors, the FDA reviewers have second thoughts re the hard line they took on the Galvus NDA.
10% of adults in China are diabetic (#msg-48221898), so Galvus ought to do pretty well in China. Beating Januvia to market certainly helps, although I presume that competition in this class is coming fairly soon.
The Lucentis market in China figures to be modest, IMO, insofar as off-label Avastin ought to be available there.
Market Data 
Markets 
AI
